Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
British Journal of Cancer|November 6, 2008
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) studyA K Koutras, K T Kalogeras, M-A Dimopoulos, et al.
The Pharmacogenomics Journal|August 17, 2011
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumabA K Koutras, A G Antonacopoulou, A G Eleftheraki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)A Bamias, U Dafni, A Karadimou, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancerE Fountzilas, J Souglakos, J Alafis, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2008
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group StudyH P Kalofonos, A Bamias, A Koutras, et al.
Breast Cancer Research and Treatment|May 17, 2008
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group studyG Fountzilas, U Dafni, M A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2005
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, D Skarlos, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, H P Kalofonos, U Dafni, et al.
Cancer Chemotherapy and Pharmacology|September 9, 2011
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trialP Skarlos, C Christodoulou, K T Kalogeras, et al.
Anticancer Research|March 12, 1998
Prognostic variables in greek patients with stage II breast cancer: a Hellenic Cooperative Oncology Group studyG Fountzilas, S Vasilaros, D Koukouras, et al.
Pageof 13